Viral sequence diversity: challenges for AIDS vaccine designs.
Among the greatest challenges facing AIDS vaccine development is the intrinsic diversity among circulating populations of HIV-1 in various geographical locations and the need to develop vaccines that can elicit enduring protective immunity to variant HIV-1 strains. While variation is observed in all of the viral proteins, the greatest diversity is localized to the viral envelope glycoproteins, evidently reflecting the predominant role of these proteins in eliciting host immune recognition and responses that result in progressive evolution of the envelope proteins during persistent infection. Interestingly, while envelope glycoprotein variation is widely assumed to be a major obstacle to AIDS vaccine development, there is very little experimental data in animal or human lentivirus systems addressing this critical issue. In this review, the state of vaccine development to address envelope diversity will be presented, focusing on the use of centralized and polyvalent sequence design as mechanisms to elicit broadly reactive immune responses.
McBurney
Sean P
SP
University of Pittsburgh, School of Medicine, Center for Vaccine Research, Program in Molecular Virology and Microbiology, Pittsburgh, PA 15261, USA. spm10@pitt.edu
Ross
Ted M
TM
D016915:AIDS Vaccines / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control* / Q000628:therapy / Q000821:virology*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D011110:Polymorphism, Genetic; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
D016915:AIDS Vaccines; D054299:env Gene Products, Human Immunodeficiency Virus